TrialCancer immunology, immunotherapy : CII2026
Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.
Panpan Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.